LKFT
Galapagos N.V. Sponsored ADR
NASDAQ · Healthcare · Biotechnology · US
$28.49
−1.83%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 990.6M | 1.1B | 275.6M | 239.7M | 241.2M |
| Cost of Revenue | 50.7M | 29.7M | 34.9M | — | — |
| Gross Profit | 939.8M | 1.1B | 240.8M | 239.7M | 241.2M |
| Operating Expenses | |||||
| R&D Expense | 237.9M | 459.4M | 335.5M | 241.3M | 269.8M |
| SG&A Expense | 107.7M | 112.0M | 96.9M | 94.3M | 103.3M |
| General & Admin Expense | 101.3M | 110.6M | 94.1M | 92.5M | 102.0M |
| Selling & Marketing Expense | 6.4M | 1.4M | 2.8M | 1.8M | 1.3M |
| Other Expenses | (15.7M) | 9.7M | (3.2M) | (7.6M) | (801.0K) |
| Total Operating Expenses | 329.9M | 581.1M | 429.1M | 328.0M | 372.3M |
| Cost and Expenses | 380.7M | 610.9M | 464.0M | 328.0M | 372.3M |
| Operating Income (EBIT) | 609.9M | 501.4M | (188.3M) | (88.3M) | (131.1M) |
| Non-Operating | |||||
| Interest Income | 25.7M | 46.3M | 89.8M | 79.6M | 18.1M |
| Interest Expense | — | 2.2M | 911.0K | 1.8M | 9.2M |
| Net Interest Income | 25.7M | 44.1M | 88.9M | 77.8M | 8.9M |
| Other Non-Op Income/Expense | (32.3M) | (200.5M) | 185.3M | 93.9M | 60.2M |
| Non-Operating Income (excl Interest) | 76.6M | 198.3M | (186.2M) | (95.7M) | (69.4M) |
| EBT (Pre-Tax Income) | 577.7M | 300.9M | (3.1M) | 5.6M | (70.8M) |
| Income Tax Expense | (16.6M) | (18.6M) | (1.8M) | 9.6M | 572.0K |
| Bottom Line | |||||
| Net Income | 596.6M | 320.9M | 74.1M | 211.7M | (218.0M) |
| Earnings from Cont. Ops | 594.3M | 319.5M | (1.3M) | (4.0M) | (71.4M) |
| Earnings from Discont. Ops | 2.3M | 1.4M | 75.4M | 215.7M | (146.6M) |
| Bottom Line Net Income | 596.4M | 320.9M | 74.1M | 211.7M | (218.0M) |
| Per Share | |||||
| Basic EPS | $9.05 | $4.87 | $1.12 | $3.21 | ($3.32) |
| Diluted EPS | $9.05 | $4.87 | $1.12 | $3.21 | ($3.32) |
| Revenue Per Share | $13.44 | $16.88 | $4.17 | $3.64 | $3.67 |
| Shares | |||||
| Basic Shares Outstanding | 73.7M | 65.9M | 66.1M | 65.9M | 65.7M |
| Diluted Shares Outstanding | 66.9M | 65.9M | 66.1M | 65.9M | 65.7M |
| Profitability Metrics | |||||
| EBITDA | 541.6M | 359.0M | 43.3M | 51.0M | 3.9M |
| D&A | 8.2M | 55.9M | 45.5M | 43.6M | 65.6M |
| EBIT | 533.4M | 303.1M | (2.2M) | 7.4M | (61.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026